Reduced ABCA1-mediated cholesterol efflux and accelerated atherosclerosis in apolipoprotein E-deficient mice lacking macrophage-derived ACAT1

Circulation

Volumn 111, Issue 18, 2005, Pages 2373-2381

  Yan, Ru Su ^a   Dove, Dwayne E ^a   Major, Amy S ^a   Hasty, Alyssa H ^b   Boone, Branden ^a   Linton, MacRae F ^a,b   Fazio, Sergio ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Acyltransferases; Apolipoproteins; Apoptosis; Atherosclerosis; Cholesterol

Indexed keywords

ABC TRANSPORTER A1; APOLIPOPROTEIN E; CHOLESTEROL; CHOLESTEROL ACYLTRANSFERASE; COMPLEMENTARY DNA; LIPOPROTEIN; TRIACYLGLYCEROL;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AORTA; APOPTOSIS; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; BONE MARROW TRANSPLANTATION; CHOLESTEROL BLOOD LEVEL; DNA MICROARRAY; GENE EXPRESSION; LIPID BLOOD LEVEL; MALE; MOUSE; NICK END LABELING; NONHUMAN; PERITONEUM MACROPHAGE; PRIORITY JOURNAL; PROTEIN SYNTHESIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ACETYL-COA C-ACETYLTRANSFERASE; ANIMALS; AORTA; APOLIPOPROTEIN A-I; APOLIPOPROTEINS E; APOPTOSIS; ATHEROSCLEROSIS; ATP-BINDING CASSETTE TRANSPORTERS; CHOLESTEROL; MACROPHAGES; MICE; MICE, KNOCKOUT;

EID: 18444396937     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000164236.19860.13     Document Type: Article

References (48)

1. Buhman KF, Accad M, Farese RV. Mammalian acyl-CoA:cholesterol acyltransferases. Biochim Biophys Acta. 2000;1529:142-154.
2. Rudel LL, Lee RG, Cockman TL. Acyl coenzyme A:cholesterol acyltransferase types 1 and 2: structure and function in atherosclerosis. Curr Opin Lipidol. 2001;12:121-127.
3. Chang TY, Chang CC, Lin S, Yu C, Li BL, Miyazaki A. Roles of acyl-coenzyme A:cholesterol acyltransferase-1 and -2. Curr Opin Lipidol. 2001;12:289-296.
4. Chang TY, Chang CC, Cheng D. Acyl-coenzyme A:cholesterol acyltransferase. Annu Rev Biochem. 1997;66:613-638.
5. Meiner V, Tam C, Gunn MD, Dong LM, Weisgraber KH, Novak S, Myers HM, Erickson SK, Farese RV Jr. Tissue expression studies on the mouse acyl-CoA:cholesterol acyltransferase gene (ACACT): findings supporting the existence of multiple cholesterol esterification enzymes in mice. J Lipid Res. 1997;38:1928-33.
6. Joyce C, Skinner K, Anderson RA, Rudel LL. Acyl-coenzyme A:cholesteryl acyltransferase 2. Curr Opin Lipidol. 1999;10:89-95.
7. Anderson RA, Joyce C, Davis M, Reagan JW, Clark M, Shelness GS, Rudel LL. Identification of a form of acyl-CoA:cholesterol acyltransferase specific to liver and intestine in nonhuman primates. J Biol Chem. 1998;273:26747-26754.
8. Cases S, Novak S, Zheng YW, Myers HM, Lear SR, Sande E, Welch CB, Lusis AJ, Spencer TA, Krause BR, Erickson SK, Farese RV Jr. ACAT-2, a second mammalian acyl-CoA:cholesterol acyltransferase: its cloning, expression, and characterization. J Biol Chem. 1998;273:26755-26764.
9. Chang CC, Huh HY, Cadigan KM, Chang TY. Molecular cloning and functional expression of human acyl-coenzyme A:cholesterol acyltransferase cDNA in mutant Chinese hamster ovary cells. J Biol Chem. 1993;268:20747-20755.
10. Oelkers P, Behari A, Cromley D, Billheimer JT, Sturley SL. Characterization of two human genes encoding acyl coenzyme A:cholesterol acyltransferase-related enzymes. J Biol Chem. 1998;273:26765-26771.
11. Kusunoki J, Hansoty DK, Aragane K, Fallon JT, Badimon JJ, Fisher EA. Acyl-CoA:cholesterol acyltransferase inhibition reduces atherosclerosis in apolipoprotein E-deficient mice. Circulation. 2001;103:2604-2609.
12. Perrey S, Legendre C, Matsuura A, Guffroy C, Binet J, Ohbayashi S, Tanaka T, Ortuno JC, Matsukura T, Laugel T, Padovani P, Bellamy F, Edgar AD. Preferential pharmacological inhibition of macrophage ACAT increases plaque formation in mouse and rabbit models of atherogenesis. Atherosclerosis. 2001;155:359-370.
13. Fazio S, Major AS, Swift LL, Gleaves LA, Accad M, Linton MF, Farese RV Jr. Increased atherosclerosis in LDL receptor-null mice lacking ACAT1 in macrophages. J Clin Invest. 2001;107:163-171.
14. Huang ZH, Lin CY, Oram JF, Mazzone T. Sterol efflux mediated by endogenous macrophage apoE expression is independent of ABCA1. Arterioscler Thromb Vasc Biol. 2001;21:2019-2025.
15. Fazio S, Babaev VR, Murray AB, Hasty AH, Carter KJ, Cleaves LA, Atkinson JB, Linton MF. Increased atherosclerosis in mice reconstituted with apolipoprotein E null macrophages. Proc Natl Acad Sci U S A. 1997;94:4647-4652.
16. Fazio S, Babaev VR, Burleigh ME, Major AS, Hasty AH, Linton MF. Physiological expression of macrophage apoE in the artery wall reduces atherosclerosis in severely hyperlipidemic mice. J Lipid Res. 2002;43:1602-1609.
17. Linton MF, Atkinson JB, Fazio S. Prevention of atherosclerosis in apolipoprotein E-deficient mice by bone marrow transplantation. Science. 1995;267:1034-1037.
18. Fazio S, Lee YL, Ji ZS, Rall SC Jr. Type III hyperlipoproteinemic phenotype in transgenic mice expressing dysfunctional apolipoprotein E. J Clin Invest. 1993;92:1497-1503.
19. Basu SK, Goldstein JL, Anderson GW, Brown MS. Degradation of cationized low density lipoprotein and regulation of cholesterol metabolism in homozygous familial hypercholesterolemia fibroblasts. Proc Natl Acad Sci U S A. 1976;73:3178-3182.
20. Lin CY, Duan H, Mazzone T. Apolipoprotein E-dependent cholesterol efflux from macrophages: kinetic study and divergent mechanisms for endogenous versus exogenous apolipoprotein E. J Lipid Res. 1999;40:1618-1627.
21. Su YR, Linton MF, Fazio S. Rapid quantification of murine ABC mRNAs by real time reverse transcriptase-polymerase chain reaction. J Lipid Res. 2002;43:2180-2187.
22. Su YR, Ishiguro H, Major AS, Dove DE, Zhang W, Hasty AH, Babaev VR, Linton MF, Fazio S. Macrophage apolipoprotein A-I expression protects against atherosclerosis in ApoE-deficient mice and up-regulates ABC transporters. Mol Ther. 2003;8:576-583.
23. Zhang W, Yancey PG, Su YR, Babaev VR, Zhang Y, Fazio S, Linton MF. Inactivation of macrophage scavenger receptor class B type I promotes atherosclerotic lesion development in apolipoprotein E-deficient mice. Circulation. 2003;108:2258-2263.
24. Deleted in proof.
25. Oram JF. The cholesterol mobilizing transporter ABCA1 as a new therapeutic target for cardiovascular disease. Trends Cardiovasc Med. 2002; 12:170-175.
26. Oram JF. ATP-binding cassette transporter A1 and cholesterol trafficking. Curr Opin Lipidol. 2002;13:373-381.
27. Oram JF. Molecular basis of cholesterol homeostasis: lessons from Tangier disease and ABCA1. Trends Mol Med. 2002;8:168-173.
28. Francone OL, Aiello RJ. ABCA1: regulation, function and relationship to atherosclerosis. Curr Opin Investig Drugs. 2002;3:415-419.
29. Porsch-Ozcurumez M, Langmann T, Heimerl S, Borsukova H, Kaminski WE, Drobnik W, Honer C, Schumacher C, Schmitz G. The zinc finger protein 202 (ZNF202) is a transcriptional repressor of ATP binding cassette transporter A1 (ABCA1) and ABCG1 gene expression and a modulator of cellular lipid efflux. J Biol Chem. 2001;276:12427-12433.
30. Putilina T, Wong P, Gentleman S. The DHHC domain: a new highly conserved cysteine-rich motif. Mol Cell Biochem. 1999;195:219-226.
31. Feng B, Tabas I. ABCA1-mediated cholesterol efflux is defective in free cholesterol-loaded macrophages: mechanism involves enhanced ABCA1 degradation in a process requiring full NPC1 activity. J Biol Chem. 2002;277:43271-43280.
32. Boisvert WA, Spangenberg J, Curtiss LK. Treatment of severe hypercholesterolemia in apolipoprotein E-deficient mice by bone marrow transplantation. J Clin Invest. 1995;96:1118-1124.
33. Bellosta S, Mahley RW, Sanan DA, Murata J, Newland DL, Taylor JM, Pitas RE. Macrophage-specific expression of human apolipoprotein E reduces atherosclerosis in hypercholesterolemic apolipoprotein E-null mice. J Clin Invest. 1995;96:2170-2179.
34. Wang ZF, Whitfield ML, Ingledue TC 3rd, Dominski Z, Marzluff WF. The protein that binds the 3′ end of histone mRNA: a novel RNA-binding protein required for histone pre-mRNA processing. Genes Dev. 1996;10: 3028-3040.
35. Levine BJ, Chodchoy N, Marzluff WF, Skoultchi AI. Coupling of replication type histone mRNA levels to DNA synthesis requires the stem-loop sequence at the 3′ end of the mRNA. Proc Natl Acad Sci U S A. 1987;84:6189-6193.
36. Hanayama R, Tanaka M, Miwa K, Shinohara A, Iwamatsu A, Nagata S. Identification of a factor that links apoptotic cells to phagocytes. Nature. 2002;417:182-187.
37. Feng B, Yao PM, Li Y, Devlin CM, Zhang D, Harding HP, Sweeney M, Rong JX, Kuriakose G, Fisher EA, Marks AR, Ron D, Tabas I. The endoplasmic reticulum is the site of cholesterol-induced cytotoxicity in macrophages. Nat Cell Biol. 2003;5:781-792.
38. Isoda K, Shiigai M, Ishigami N, Matsuki T, Horai R, Nishikawa K, Kusuhara M, Nishida Y, Iwakura Y, Ohsuzu F. Deficiency of interleukin-1 receptor antagonist promotes neointimal formation after injury. Circulation. 2003;108:516-518.
39. von der Thusen JH, Kuiper J, van Berkel TJ, Biessen EA. Interleukins in atherosclerosis: molecular pathways and therapeutic potential. Pharmacol Rev. 2003;55:133-166.
40. Devlin CM, Kuriakose G, Hirsch E, Tabas I. Genetic alterations of IL-1 receptor antagonist in mice affect plasma cholesterol level and foam cell lesion size. Proc Natl Acad Sci U S A. 2002;99:6280-6285.
41. Elhage R, Maret A, Pieraggi MT, Thiers JC, Arnal JF, Bayard F. Differential effects of interleukin-1 receptor antagonist and tumor necrosis factor binding protein on fatty-streak formation in apolipoprotein E-deficient mice. Circulation. 1998;97:242-244.
42. Libby P, Aikawa M. Vitamin C, collagen, and cracks in the plaque. Circulation. 2002;105:1396-1398.
43. Barnes MJ, Farndale RW. Collagens and atherosclerosis. Exp Gerontol. 1999;34:513-525.
44. Accad M, Smith SJ, Newland DL, Sanan DA, King LE Jr, Linton MF, Fazio S, Farese RV Jr. Massive xanthomatosis and altered composition of atherosclerotic lesions in hyperlipidemic mice lacking acyl CoA:cholesterol acyltransferase 1. J Clin Invest. 2000;105:711-719.
45. Yagyu H, Kitamine T, Osuga J, Tozawa R, Chen Z, Kaji Y, Oka T, Perrey S, Tamura Y, Ohashi K, Okazaki H, Yahagi N, Shionoiri F, Iizuka Y, Harada K, Shimano H, Yamashita H, Gotoda T, Yamada N, Ishibashi S. Absence of ACAT-1 attenuates atherosclerosis but causes dry eye and cutaneous xanthomatosis in mice with congenital hyperlipidemia. J Biol Chem. 2000;275:21324-21330.
46. Sugimoto K, Tsujita M, Wu CA, Suzuki K, Yokoyama S. An inhibitor of acylCoA:cholesterol acyltransferase increases expression of ATP-binding cassette transporter Al and thereby enhances the ApoA-I-mediated release of cholesterol from macrophages. Biochim Biophys Acta. 2004; 1636:69-76.
47. Rodriguez A, Usher DC. Anti-atherogenic effects of the acyl-CoA:cholesterol acyltransferase inhibitor, avasimibe (CI-1011), in cultured primary human macrophages. Atherosclerosis. 2002;161:45-54.
48. Willner EL, Tow B, Buhman KK, Wilson M, Sanan DA, Rudel LL, Farese RV Jr. Deficiency of acyl CoA:cholesterol acyltransferase 2 prevents atherosclerosis in apolipoprotein E-deficient mice. Proc Natl Acad Sci U S A. 2003;100:1262-1267.